109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
自体血清与非培养表皮细胞悬液治疗稳定期白癜风：30 例病例系列研究
Authors Liang J, Liang J, Jiang Y, Li W, Feng W, Yang Y, Liu B, Chen N, Wang H, Zhang X
Received 18 July 2025
Accepted for publication 9 October 2025
Published 12 November 2025 Volume 2025:18 Pages 2995—3004
DOI https://doi.org/10.2147/CCID.S552077
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Anne-Claire Fougerousse
Jingyao Liang,1,2 Jingfeng Liang,3 Yu Jiang,1,2 Wei Li,1,2 Wei Feng,3 Yuxin Yang,3 Bin Liu,3 Ning Chen,3 Haijun Wang,3 Xibao Zhang1,2
1Institute of Dermatology, Guangzhou Medical University, Guangzhou, 510095, People’s Republic of China; 2Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, 510095, People’s Republic of China; 3Guangzhou New Century Institute of Vitiligo, Guangzhou, 510000, People’s Republic of China
Correspondence: Xibao Zhang, Institute of Dermatology, Guangzhou Medical University, Guangzhou, 510095, People’s Republic of China, Email gzpfbfzs@163.com Haijun Wang, Guangzhou New Century Institute of Vitiligo, Guangzhou, 510000, People’s Republic of China, Email 962822778@qq.com
Background: Stable vitiligo, characterized by irreversible melanocyte loss, often resists conventional therapies. Non-cultured epidermal cell suspension (NCES) transplantation are increasingly used, and adjunctive autologous serum may enhance efficacy via growth factor-mediated cell survival and proliferation. This study evaluates the clinical outcomes of combined autologous serum and NCES therapy for stable vitiligo.
Methods: This prospective case series enrolled 30 patients (61 sites) with stable vitiligo at the Guangzhou New Centre Institute of Vitiligo (2024– 2025). Patients received autologous serum followed by NCES transplantation. Repigmentation was assessed using the Vitiligo Area Scoring Index (VASI) and color matching. Adverse events were monitored.
Results: After 3 to 6 months, excellent repigmentation (> 90%) was achieved in 83.6% of treated sites (51/61), with particularly high efficacy on facial (90% efficacy in 9/10 sites) and neck regions (92.3% efficacy in 12/13 sites). The trunk, upper limbs, and hands/fingers exhibited excellent repigmentation in 80.0%, 77.8%, and 78.6% of sites, respectively. Poor repigmentation (< 25%) was observed in only one trunk site (1/61). Excellent color matching was achieved in 82.0% of treated sites (50/61), and no treatment-related adverse effects were reported.
Conclusion: The combination of autologous serum and NCES transplantation is highly effective and safe for stable vitiligo. Autologous serum may synergize with NCES by supporting the microenvironment for melanocyte engraftment, offering a promising strategy for stable vitiligo.
Keywords: vitiligo, non-cultured epidermal cell suspension, autologous serum, melanocytes
1Institute of Dermatology, Guangzhou Medical University, Guangzhou, 510095, People’s Republic of China; 2Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, 510095, People’s Republic of China; 3Guangzhou New Century Institute of Vitiligo, Guangzhou, 510000, People’s Republic of China
Correspondence: Xibao Zhang, Institute of Dermatology, Guangzhou Medical University, Guangzhou, 510095, People’s Republic of China, Email gzpfbfzs@163.com Haijun Wang, Guangzhou New Century Institute of Vitiligo, Guangzhou, 510000, People’s Republic of China, Email 962822778@qq.com
Background: Stable vitiligo, characterized by irreversible melanocyte loss, often resists conventional therapies. Non-cultured epidermal cell suspension (NCES) transplantation are increasingly used, and adjunctive autologous serum may enhance efficacy via growth factor-mediated cell survival and proliferation. This study evaluates the clinical outcomes of combined autologous serum and NCES therapy for stable vitiligo.
Methods: This prospective case series enrolled 30 patients (61 sites) with stable vitiligo at the Guangzhou New Centre Institute of Vitiligo (2024– 2025). Patients received autologous serum followed by NCES transplantation. Repigmentation was assessed using the Vitiligo Area Scoring Index (VASI) and color matching. Adverse events were monitored.
Results: After 3 to 6 months, excellent repigmentation (> 90%) was achieved in 83.6% of treated sites (51/61), with particularly high efficacy on facial (90% efficacy in 9/10 sites) and neck regions (92.3% efficacy in 12/13 sites). The trunk, upper limbs, and hands/fingers exhibited excellent repigmentation in 80.0%, 77.8%, and 78.6% of sites, respectively. Poor repigmentation (< 25%) was observed in only one trunk site (1/61). Excellent color matching was achieved in 82.0% of treated sites (50/61), and no treatment-related adverse effects were reported.
Conclusion: The combination of autologous serum and NCES transplantation is highly effective and safe for stable vitiligo. Autologous serum may synergize with NCES by supporting the microenvironment for melanocyte engraftment, offering a promising strategy for stable vitiligo.
Keywords: vitiligo, non-cultured epidermal cell suspension, autologous serum, melanocytes